🎉 M&A multiples are live!
Check it out!

Sutro Biopharma Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sutro Biopharma and similar public comparables like Pharming, Vivoryon Therapeutics, and Benevolent AI.

Sutro Biopharma Overview

About Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.


Founded

2003

HQ

United States of America
Employees

338

Website

sutrobio.com

Financials

LTM Revenue $57.8M

LTM EBITDA -$213M

EV

-$244M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Sutro Biopharma Financials

Sutro Biopharma has a last 12-month revenue of $57.8M and a last 12-month EBITDA of -$213M.

In the most recent fiscal year, Sutro Biopharma achieved revenue of $62.0M and an EBITDA of -$187M.

Sutro Biopharma expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Sutro Biopharma valuation multiples based on analyst estimates

Sutro Biopharma P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $154M $62.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$58.0M -$187M XXX XXX XXX
EBITDA Margin -38% -301% XXX XXX XXX
Net Profit -$119M -$107M XXX XXX XXX
Net Margin -78% -172% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Sutro Biopharma Stock Performance

As of April 15, 2025, Sutro Biopharma's stock price is $1.

Sutro Biopharma has current market cap of $50.0M, and EV of -$244M.

See Sutro Biopharma trading valuation data

Sutro Biopharma Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$244M $50.0M XXX XXX XXX XXX $-2.70

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Sutro Biopharma Valuation Multiples

As of April 15, 2025, Sutro Biopharma has market cap of $50.0M and EV of -$244M.

Sutro Biopharma's trades at -4.2x LTM EV/Revenue multiple, and 1.1x LTM EBITDA.

Analysts estimate Sutro Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Sutro Biopharma and 10K+ public comps

Sutro Biopharma Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$244M XXX XXX XXX
EV/Revenue -3.9x XXX XXX XXX
EV/EBITDA 1.3x XXX XXX XXX
P/E -0.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Sutro Biopharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Sutro Biopharma Valuation Multiples

Sutro Biopharma's NTM/LTM revenue growth is -16%

Sutro Biopharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Sutro Biopharma's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Sutro Biopharma's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Sutro Biopharma and other 10K+ public comps

Sutro Biopharma Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -60% XXX XXX XXX XXX
EBITDA Margin -301% XXX XXX XXX XXX
EBITDA Growth 222% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -317% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 78% XXX XXX XXX XXX
R&D Expenses to Revenue 406% XXX XXX XXX XXX
Opex to Revenue 484% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Sutro Biopharma Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Sutro Biopharma M&A and Investment Activity

Sutro Biopharma acquired  XXX companies to date.

Last acquisition by Sutro Biopharma was  XXXXXXXX, XXXXX XXXXX XXXXXX . Sutro Biopharma acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Sutro Biopharma

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Sutro Biopharma

When was Sutro Biopharma founded? Sutro Biopharma was founded in 2003.
Where is Sutro Biopharma headquartered? Sutro Biopharma is headquartered in United States of America.
How many employees does Sutro Biopharma have? As of today, Sutro Biopharma has 338 employees.
Who is the CEO of Sutro Biopharma? Sutro Biopharma's CEO is Ms. Jane Chung.
Is Sutro Biopharma publicy listed? Yes, Sutro Biopharma is a public company listed on NAS.
What is the stock symbol of Sutro Biopharma? Sutro Biopharma trades under STRO ticker.
When did Sutro Biopharma go public? Sutro Biopharma went public in 2018.
Who are competitors of Sutro Biopharma? Similar companies to Sutro Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Sutro Biopharma? Sutro Biopharma's current market cap is $50.0M
What is the current revenue of Sutro Biopharma? Sutro Biopharma's last 12-month revenue is $57.8M.
What is the current EBITDA of Sutro Biopharma? Sutro Biopharma's last 12-month EBITDA is -$213M.
What is the current EV/Revenue multiple of Sutro Biopharma? Current revenue multiple of Sutro Biopharma is -4.2x.
What is the current EV/EBITDA multiple of Sutro Biopharma? Current EBITDA multiple of Sutro Biopharma is 1.1x.
What is the current revenue growth of Sutro Biopharma? Sutro Biopharma revenue growth between 2023 and 2024 was -60%.
Is Sutro Biopharma profitable? Yes, Sutro Biopharma is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.